Single Dose Packaging Key Players and their Developments
The global single dose packaging market size reached US$ 68.38 billion in 2023 and is projected to hit around US$ 141.73 billion by 2034, expanding at a CAGR of 6.85% during the forecast period from 2024 to 2034. North America dominated the single dose packaging market in 2023 while Asia Pacific is expected to grow at a significant rate in the market.
Global Single Dose Packaging Market Key Players
- Unit Pack Company Inc.
- Gerresheimer AG.
- West Pharmaceutical Services, Inc.
- Catalent, Inc.
- Schott AG
- Adelphi Healthcare Packaging
- Nipro Corporation
- Berry Global, Inc
- Aptar Group, Inc.
- Amcor plc
- Comar LLC
- Pacific Vial Manufacturing Inc.
- Sonoco Products
- Klockner Pentaplast Group
- Constantia Flexible Group GmbH
- Shandong Pharmaceutical
- Avesta Continental Pack
- Shanghai Tongpeng Electric Material Co
- Tonbay Industry Co
- Jinan Youlyy Industrial Co
- Khemka Glass
- Dibar Labs
- Ropack Pharma Solutions
- Stevanato Group
- Shako Flexipack Pvt. Ltd
- Glenroy
- Polymer Packaging Inc
- Richards Glass Co. Ltd
- Uflex Limited
- Cheer Pack North America
- Farcoderma S.r.I.
- Skyepharma
U.S. Import: Top 10 Loading Ports by Quantity for Single Dose Packaging (HS Code 3006 – Pharmaceutical Goods)
(November 2023 - December 2024)
| Loading Port |
Quantity (Units) |
| 20505, SANTO TOMAS |
748,391 |
| 24741, RIO HAINA |
724,201 |
| 42305, ANVERS |
4,431,739 |
| 55206, VUNG TAU |
722,531 |
| 57020, NINGPO |
2,060,657 |
| 57035, SHANGHAI |
4,385,097 |
| 57037 |
1,628,818 |
| 57047, QINGDAO |
713,512 |
| 57078, YANTIAN |
1,792,668 |
| 58023, PUSAN |
825,554 |
New Advancements in Single Dose Packaging Industry
- In November 2024, Viatris Inc.'s U.S. unit-dose packaging business has been acquired by Safecor Health, the industry leader in pharmaceutical unit-dose repackaging and supply chain solutions. Previously, the company was called Unit Dose Laboratories, or UDL. Adding the UDL team, the strong brand recognition, and their capabilities to the Safecor family will further the company’s ongoing aim of offering world-class packaging and supply chain solutions to the manufacturers and health systems the company serve. Mark Saxon, CEO of Safecor, added, with this addition, the company will immediately expand the number of unit-dose commercial products company offer, and Safecor company plan to increase the offering with expanded manufacturer, health system, and wholesaler relationships.
- In October 2024, In the US, Sandoz, the world leader in generic and biosimilar drugs, today announced the launch of a generic version of paclitaxel, the first generic version of its reference medication to receive FDA approval. Injectable suspension of Sandoz paclitaxel protein-bound particles (albumin-bound) is recommended for the treatment of individuals with metastatic breast cancer. The FDA approved the lyophilized powder for injection on October 8, 2024, offering 100 mg of pacitaxel in a single-dose vial for intravenous usage.
